Preclinical Results Presented at the American Society of Hematology Annual Meeting SEATTLE, Dec 08, 2008 (BUSINESS WIRE) -- Calistoga Pharmaceuticals, Inc., the leader in the development of ...

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and ...

Targeted therapy with imatinib has transformed the treatment of chronic myeloid leukemia (CML). Unlike CML, chronic lymphocytic leukemia (CLL) lacks a common genetic aberration but does demonstrate ...

Researchers have demonstrated that selective inactivation of the p110&alpha, PI3K isoform is sufficient to block tumor progression and metastasis in a mice model of PanNETs Researchers from the ...

ScienceDaily (Aug. 10, 2010) - Research at the Babraham Institute, investigating how white blood cells known as B cells develop, has revealed that genes from the Phosphatidylinositol 3-kinase (PI3Ks) ...

DUBLIN--(BUSINESS WIRE)--The "Copiktra" report has been added to ResearchAndMarkets.com's offering. Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the ...

Although significant progress has been made in the treatment and management of patients with FL, several challenges remain, including the need to develop better prognostic models and markers for ...

The phosphatidylinositol 3-kinases (PI3Ks) regulate cell growth, proliferation and survival, and are frequently affected in human cancer. PI3K is composed of a catalytic subunit, p110, and a ...

Myriad of Groups Are Working on the Latest Hot Target and Most Are Optimistic About Its Potential Although the term “signal transduction” was coined back in 1972, cell-signaling switches have only ...

Karus Therapeutics is teaming up with the Babraham Institute to further characterize novel treatments for inflammatory diseases. The partners plan to achieve this through the regulation of ...